Navigation Links
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Date:1/8/2009

Kidney transplantation to be Quark's second indication with clinical-stage, systemically administered siRNA product candidate

FREMONT, Calif., Jan. 8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that it has initiated patient dosing in its Phase I/II clinical trial evaluating its systemically administered siRNA drug candidate QPI-1002 (previously referred to as DGFi) for prevention of Delayed Graft Function (DGF) in patients undergoing deceased donor kidney transplantation. DGF represents Quark's second indication being evaluated for the systemically administered dug candidate in human clinical trials. This trial follows two currently enrolling Phase I clinical trials in acute kidney injury (AKI).

The multi-center, two-part Phase I/II clinical trial in DGF is expected to enroll up to 204 adult kidney transplant recipients. The first part of the study is a dose-escalation design to evaluate the safety and tolerability of a single intravenous injection of QPI-1002 in renal transplant patients at high risk to develop DGF. The second part of the study will evaluate safety and potential clinical activity of a selected dose of QPI-1002 in the same patient population. Patients will be enrolled in clinical sites in the United States.

Shai Erlich, Ph.D., Chief Medical Officer of Quark, commented, "The initiation of patient dosing with QPI-1002 is an important milestone for Quark as well as being an innovative approach to offer therapeutic benefit to adult kidney transplant patients at high risk for developing DGF. The siRNA drug candidate is based on the proprietary concept of Quark and reflects Quark's success in developing products originating from conceptually novel internal developments. These accomplishments further validate Quark's ability to advance innovative product candida
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013   BioCision , a leader in ... in many areas of medical and scientific research, ... the U.S. Patent Office that apply to two ... sample handling to ensure the consistency of test ... procedures. Patent number 8,388,912 covers ...
(Date:6/19/2013)... India , June 19, 2013 ... Bureau has recently added DrugPatentWatch to ... ( http://www.bharatbook.com/drugpatentwatch-tour.pdf )      ... provides comprehensive information on pharmaceutical, drug ... information supports the critical business functions ...
(Date:6/19/2013)... , June 19, 2013 Amerivet ... company servicing all branches of government from Federal ... have expanded their facilities to include complex metal ... and fabricated some very complex aluminum parts for ... to expand our capabilities to service government contracts," ...
Breaking Medicine Technology:BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2Drug Patent Watch 2Drug Patent Watch 3Amerivet Solutions Expands to Manufacture Complex Metal Designs 2
... SAN DIEGO, June 2, 2011 Biocept, Inc. today ... a poster at the 2011 Annual Meeting of the ... Chicago, Illinois June 3-7. The poster presentation is based ... logy C ell E nrichment and ...
... Kaiser Permanente Hawaii has received the inaugural Pharmacy ... Permanente,s achievement of a 5-star rating on the PQA ... Centers for Medicare and Medicaid Services (CMS) Star Rating ... because it uses publicly available quality data from CMS," ...
Cached Medicine Technology:Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs) 2Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs) 3PQA Recognizes Kaiser Permanente Hawaii for Excellence in Medication Safety 2
(Date:6/20/2013)... Hills, CA (PRWEB) June 20, 2013 ... M. Amron, has been named by The Patient’s Guide ... an expert in liposuction, Dr. Amron will now be ... Guide. The Patient's Guide sees over one million visitors ... information and articles related to plastic surgery and dermatology, ...
(Date:6/20/2013)... Dallas, Texas (PRWEB) June 20, 2013 ... of The Rhinoplasty Society, society president and keynote ... the past, present and future of rhinoplasty (plastic ... visiting the city from across the nation. ... from past closed-technique non-individualized rhinoplasty to current open-technique ...
(Date:6/20/2013)... Naples, FL (PRWEB) June 20, 2013 ... for a new-to-market supplement, Amaçari , made from ... energy boost is derived from the very high levels ... harvested Camu Camu berries from the Amazonian river basin ... a natural alternative for general health and wellbeing. , ...
(Date:6/20/2013)... InventHelp, America’s largest invention submission company, ... from Indiana, has designed hospital attire that could provide ... patented. , “Norma Jean’s” would feature ... strips along the sleeves. This design would allow hospital ... scans without the need to remove the patients clothing. ...
(Date:6/20/2013)... According to a new market research report ... DC Servo Motors/Drives, Brushless Servo Motors), Voltage Range (Low Voltage, ... - (2013 – 2018)" published by MarketsandMarkets, the total market ... by 2018, growing at an estimated CAGR of 6% from ... 102 Market Data Tables , 27 Figures ...
Breaking Medicine News(10 mins):Health News:Liposuction Guru, Dr. David Amron, Receives Award From The Patient’s Guide 2Health News:Dr. Rod J. Rohrich Delivers Keynote Address on the Future of Rhinoplasty 2Health News:Dr. Rod J. Rohrich Delivers Keynote Address on the Future of Rhinoplasty 3Health News:Dr. Rod J. Rohrich Delivers Keynote Address on the Future of Rhinoplasty 4Health News:Amaçari’s Alternative Health & Wellbeing Benefits 2Health News:InventHelp® Client Patents “Norma Jean’s” – Invention Could Keep Patients Warm and Comfortable 2Health News:Servo Motors & Drives Market to Reach 17.2 Million Units by 2018 - New Report by MarketsandMarkets 2Health News:Servo Motors & Drives Market to Reach 17.2 Million Units by 2018 - New Report by MarketsandMarkets 3
... the market-leading provider,of software for the control, management ... manage its interactions with the,media through the use ... the world,s leading pharmaceutical companies, is a,truly international ... with its,corporate office in London and major Research ...
... RIDGEWOOD, N.J., March 19 Goosie, LLC announced ... of Autism Awareness,Month throughout the month of April ... supporting families of autistic children with special,discounts. Goosie ... called,Goosie Cards(R). Goosie Cards are created online at ...
... Chronic fatigue syndrome (CFS) and fibromyalgia (FM) are ... cause and limited treatment options. However, results of ... treatment process that could help alleviate symptoms for ... M.D., medical director of the Holtorf Medical Group ...
... 19 Provena Mercy,Medical Center, a 356-bed ... levels of efficiency and physician satisfaction using ... solution from MedQuist (Pink Sheets: MEDQ). Radiologists ... percent of their,reports, and report turnaround time ...
... fast and precise ... ALTO, Calif., March 19 Varian Medical,Systems (NYSE: ... centers in North,America and Europe to further the development ... fast and precise,cancer treatments. RapidArc makes it possible to ...
... Dominate Market Despite Patent Expiries and, Increased Use of Fixed-Dose ... ... Decision Resources, WALTHAM, Mass., March 19 Decision Resources, one ... finds that sales of dyslipidemia therapies will decline,from $28 billion in ...
Cached Medicine News:Health News:Solcara Helps AstraZeneca Set International Benchmark for Global Media Relations 2Health News:Solcara Helps AstraZeneca Set International Benchmark for Global Media Relations 3Health News:Goosie Cards to Support Autism Awareness Month With Special Discount Program 2Health News:Data study suggests cortisol could alleviate for chronic fatigue syndrome and fibromyalgia 2Health News:Illinois Radiologists Self-Edit Reports, Reduce Turnaround Time with SpeechQ for Radiology(TM) 2Health News:Illinois Radiologists Self-Edit Reports, Reduce Turnaround Time with SpeechQ for Radiology(TM) 3Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 2Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 3Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 4Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 5Health News:Significant Generic Erosion Will Cause Sales of Dyslipidemia Drugs to Decline by $3.6 Billion by 2016 2
(1/4-15 LPM). 50 psi back inlet, wall mounted, 1/8" NPT female....
Value-Line oxygen flowmeters. ,Options: , For security chain, add suffix S to model number. Example: FMQ107S. , For Canadian Color-Code, add suffix FMQ104C. , For Double Flowmeters with Power Take-Of...
... Slim Line Flowmeters with brass ... For security chain, add suffix S ... For Canadian Color-Code, add suffix C ... For Double Flowmeters with Power Take-Off, ...
... Oxygen Adult Flowmeters, ,Options: ... suffix S to model number. ... Color-Code, add suffix C to ... For Double Flowmeters with Power ...
Medicine Products: